Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for 89BIO (ETNB : NSDQ)
 
 • Company Description   
89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.64 Daily Weekly Monthly
20 Day Moving Average: 297,536 shares
Shares Outstanding: 20.35 (millions)
Market Capitalization: $53.73 (millions)
Beta: 2.82
52 Week High: $23.07
52 Week Low: $2.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.33% 0.44%
12 Week -37.88% -32.60%
Year To Date -79.80% -75.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
142 SANSOME STREET SECOND FLOOR
-
SAN FRANCISCO,CA 94104
USA
ph: 415-432-9270
fax: -
investors@89bio.com http://www.89bio.com
 
 • General Corporate Information   
Officers
Rohan Palekar - Chief Executive Officer
Ryan Martins - Chief Financial Officer
Steven Altschuler - Director
Derek DiRocco - Director
Gregory Grunberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 282559103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 20.35
Most Recent Split Date: (:1)
Beta: 2.82
Market Capitalization: $53.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.52
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -70.27%
vs. Previous Quarter: 3.08%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -73.63
12/31/21 - -56.71
09/30/21 - -42.89
ROA
03/31/22 - -62.29
12/31/21 - -50.71
09/30/21 - -40.24
Current Ratio
03/31/22 - 7.36
12/31/21 - 8.29
09/30/21 - 8.42
Quick Ratio
03/31/22 - 7.36
12/31/21 - 8.29
09/30/21 - 8.42
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.05
12/31/21 - 6.21
09/30/21 - 7.31
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.14
12/31/21 - 0.13
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 12.35
12/31/21 - 11.83
09/30/21 - 0.97
 

Powered by Zacks Investment Research ©